Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus is a paper indexed in PICO Portal from OpenAlex.
How many citations does Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus have?
Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus has 65 citations in the OpenAlex counts PICO Portal stores.
When was Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus published?
Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus has 2018 year in the PICO Portal index.
What is the open-access status of Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus?
Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus has hybrid oa status in the PICO Portal index.
What is the DOI of Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus?
The DOI for Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus is on the source record.
What is the PMID of Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus?
The PMID for Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus is on the source record.
What is the OpenAlex record for Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus?
The OpenAlex for Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus is on the source record.